Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 May;20(5):1111-1120.
doi: 10.1111/dom.13194. Epub 2018 Jan 25.

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Richard E Pratley  1 , Roy Eldor  2 , Annaswamy Raji  2 , Gregory Golm  2 , Susan B Huyck  2 , Yanping Qiu  3 , Sheila Sunga  2 , Jeremy Johnson  2 , Steven G Terra  4 , James P Mancuso  5 , Samuel S Engel  2 , Brett Lauring  2
Affiliations
Randomized Controlled Trial

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial

Richard E Pratley et al. Diabetes Obes Metab. 2018 May.

Abstract

Aim: To evaluate the efficacy and safety of ertugliflozin and sitagliptin co-administration vs the individual agents in patients with type 2 diabetes who are inadequately controlled with metformin.

Methods: In this study (Clinicaltrials.gov NCT02099110), patients with glycated haemoglobin (HbA1c) ≥7.5% and ≤11.0% (≥58 and ≤97 mmol/mol) with metformin ≥1500 mg/d (n = 1233) were randomized to ertugliflozin 5 (E5) or 15 (E15) mg/d, sitagliptin 100 mg/d (S100) or to co-administration of E5/S100 or E15/S100. The primary endpoint was change from baseline in HbA1c at Week 26.

Results: At Week 26, least squares mean HbA1c reductions from baseline were greater with E5/S100 (-1.5%) and E15/S100 (-1.5%) than with individual agents (-1.0%, -1.1% and -1.1% for E5, E15 and S100, respectively; P < .001 for all comparisons). HbA1c <7.0% (<53 mmol/mol) was achieved by 26.4%, 31.9%, 32.8%, 52.3% and 49.2% of patients in the E5, E15, S100, E5/S100 and E15/S100 groups, respectively. Fasting plasma glucose reductions were significantly greater with E5/S100 and E15/S100 compared with individual agents. Body weight and systolic blood pressure (SBP) significantly decreased with E5/S100 and E15/S100 vs S100 alone. Glycaemic control, body weight and SBP effects of ertugliflozin were maintained to Week 52. Genital mycotic infections were more common among ertugliflozin-treated patients compared with those treated with S100. Incidences of symptomatic hypoglycaemia and adverse events related to hypovolaemia or urinary tract infection were similar among groups.

Conclusions: In patients with uncontrolled type 2 diabetes while using metformin, co-administration of ertugliflozin and sitagliptin provided more effective glycaemic control through 52 weeks compared with the individual agents.

Keywords: DPP-IV inhibitor; SGLT2 inhibitor; clinical trial; glycaemic control; phase III study; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

R. E. P. is a consultant (fees paid to institution) for AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd, Janssen Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Lilly, Merck & Co., Inc., Kenilworth, New Jersey, Novo Nordisk Inc. and Takeda; has received research support from Merck & Co., Inc., Kenilworth, New Jersey, Sanofi‐Aventis US, LLC, Takeda, Lilly and Novo Nordisk Inc.; is on speaker's bureaus (fees paid to institution) for AstraZeneca and Novo Nordisk Inc.; and reports other funding from Novo Nordisk Inc. A. R., G. G., S. B. H., S. S., J. J, S. S. E. and B. L. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, and may own stock and/or hold stock options in the company. R. E. was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey at the time the study was conducted. Y. Q. is an employee of MSD R & D (China) Co., Ltd., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey and may own stock and/or hold stock options in the company. S. G. T. and J. P. M. are employees and shareholders of Pfizer Inc.

Figures

Figure 1
Figure 1
Change over time in (A), glycated haemoglobin (HbA1c) (%) and (B), body weight (kg). LS, least squares; SE, standard error
See this image and copyright information in PMC

References

    1. American Diabetes Association . 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40:S64‐S74. - PubMed
    1. Scheen AJ. Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP‐4 inhibitor combination therapy in type 2 diabetes. Clin Pharmacokinet. 2017;56:703‐718. - PubMed
    1. Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF‐04971729, a selective inhibitor of the sodium‐dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39:1609‐1619. - PubMed
    1. Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591‐598. - PubMed
    1. Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19:721‐728. - PubMed

Publication types

MeSH terms

Associated data